1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Ascentage Pharma Group International
  6. Summary
    6855   KYG0519B1023

ASCENTAGE PHARMA GROUP INTERNATIONAL

(6855)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
05/10/2022 05/11/2022 05/12/2022 05/13/2022 05/16/2022 Date
11.98(c) 12.04(c) 11.66(c) 11.78(c) 11.9(c) Last
1 042 908 1 432 700 661 400 774 600 439 059 Volume
+1.87% +0.50% -3.16% +1.03% +1.02% Change
More quotes
Estimated financial data (e)
Sales 2022 198 M 29,1 M 29,1 M
Net income 2022 -944 M -139 M -139 M
Net Debt 2022 - - -
P/E ratio 2022 -2,98x
Yield 2022 -
Sales 2023 1 135 M 167 M 167 M
Net income 2023 -619 M -91,2 M -91,2 M
Net Debt 2023 - - -
P/E ratio 2023 -4,67x
Yield 2023 -
Capitalization 2 652 M 391 M 391 M
Capi. / Sales 2022 13,4x
Capi. / Sales 2023 2,34x
Nbr of Employees 613
Free-Float 63,0%
More Financials
Company
Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and... 
More about the company
Ratings of Ascentage Pharma Group International
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ASCENTAGE PHARMA GROUP INTERNATIONAL
04/13Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Me..
CI
03/22US FDA Grants Rare Pediatric Disease Designation to Ascentage Pharma's Cancer Medicine
MT
03/22Ascentage Pharma Narrows Per-Share Loss in 2021 on Higher Revenue; Shares Jump 6%
MT
03/21Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended D..
CI
03/15Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study o..
PR
03/15Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study o..
CI
03/14Ascentage Pharma Doses First Patient in Phase II Trial of Leukemia, Lymphoma Treatment
MT
03/08Ascentage Pharma to Present Data From Preclinical Trials of 5 Tumor Treatment at Oncolo..
MT
03/08Ascentage Pharma Group International to Present Latest Results from Six Preclinical Stu..
CI
01/05Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference
PR
2021Ascentage Pharma Presents Updated Data From 6 Studies of Cancer Treatments; Shares Slum..
MT
2021Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lis..
CI
2021Ascentage Pharma Wins Nod for China Phase 2 Study of Leukemia, Lymphoma Treatment; Shar..
MT
2021Ascentage Pharma Announces CDE's Approval for the Phase II Pivotal Study in China of th..
CI
2021Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Hum..
AQ
More news
News in other languages on ASCENTAGE PHARMA GROUP INTERNATIONAL
04/13Ascentage Pharma présente les derniers résultats de six études précliniques au congrès ..
03/22Ascentage Pharma réduit sa perte par action en 2021 grâce à l'augmentation des recettes..
03/21Ascentage Pharma Group International annonce ses résultats pour l'exercice complet clos..
03/15Ascentage Pharma annonce le dosage du premier patient en Chine dans l'étude pivot de ph..
03/08Ascentage Pharma Group International présentera les derniers résultats de six études pr..
More news
Chart ASCENTAGE PHARMA GROUP INTERNATIONAL
Duration : Period :
Ascentage Pharma Group International Technical Analysis Chart | 6855 | KYG0519B1023 | MarketScreener
Technical analysis trends ASCENTAGE PHARMA GROUP INTERNATIONAL
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 10,29 CNY
Average target price 30,07 CNY
Spread / Average Target 192%
EPS Revisions
Managers and Directors
Da Jan Yang Chairman & Chief Executive Officer
Ming Guo President
Yi Qing Chen Chief Financial Officer
Chang Qing Ye Independent Non-Executive Director
Zheng Yin Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ASCENTAGE PHARMA GROUP INTERNATIONAL-58.23%387
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-14.92%43 023
BIONTECH SE-38.39%38 601